Cardiff Oncology to Present Updated Phase 2 Data for Onvansertib in mCRC
Event summary
- Cardiff Oncology will host an investor webcast on June 3, 2026, to discuss updated Phase 2 CRDF-004 data for onvansertib in first-line RAS-mutated metastatic colorectal cancer (mCRC).
- The updated data will first be presented at the 2026 ASCO Annual Meeting on June 2, 2026.
- Onvansertib, a highly specific oral PLK1 inhibitor, is being evaluated in combination with standard-of-care regimens (FOLFIRI/bevacizumab or FOLFOX/bevacizumab).
- The 30 mg dose of onvansertib in combination with FOLFIRI/bevacizumab has been selected for advancement into a registrational trial.
The big picture
Cardiff Oncology's focus on PLK1 inhibition positions it in a competitive oncology space where targeted therapies are increasingly critical. The updated data for onvansertib could validate its potential as a novel treatment for RAS-mutated mCRC, a patient population with high unmet medical needs. The strategic move to advance the 30 mg dose into a registrational trial underscores the company's confidence in the drug's efficacy and its intent to capture a significant share of the mCRC market.
What we're watching
- Clinical Efficacy
- How the updated Phase 2 data will impact the regulatory pathway for onvansertib in first-line RAS-mutated mCRC.
- Market Positioning
- Whether Cardiff Oncology can leverage these results to secure partnerships or licensing deals for onvansertib.
- Execution Risk
- The pace at which Cardiff Oncology can advance onvansertib into a registrational trial and potential approval.
Related topics